All endocrine glands are susceptible to neoplastic growth, yet the health consequences of
these neoplasms differ between endocrine tissues. Pituitary neoplasms are highly prevalent …

The classification of adenohypophysial neoplasms as “pituitary neuroendocrine
tumors”(PitNETs) was proposed in 2017 to reflect their characteristics as epithelial …

Aggressive pituitary tumors (APTs) and pituitary carcinomas (PCs) are heterogeneous with
regard to clinical presentation, proliferative markers, clinical course, and response to …

Once temozolomide has failed, there is no recommended treatment option for pituitary
carcinomas and aggressive pituitary tumors. Immune-checkpoint inhibitors (ICIs) represent …

Abstract Context Aggressive pituitary tumors (APTs) are characterized by unusually rapid
growth and lack of response to standard treatment. About 1% to 2% develop metastases …

Survival for patients with aggressive pituitary tumours (APT) and pituitary carcinomas (PC)
has significantly improved following the increasing use of temozolomide (TMZ) since the first …

Pituitary tumors are generally benign, although in rare cases aggressive pituitary tumors
(APTs) and carcinomas present important diagnostic and therapeutic challenges and are …

Aggressive pituitary tumors (APTs) are associated with significant morbidity and mortality,
and effective treatment options are limited. Immune checkpoint inhibitors (ICIs) have …

Introduction Safranal is an active component of the traditional Tibetan medicine (TTM)
saffron, which has potential anticancer activity. Methods and results Here, we studied the …

Purpose Refractory prolactinomas resistant to dopamine agonists (DAs) pose a clinical
challenge. Temozolomide (TMZ) is a recommended treatment option, but its effects are …